image
Healthcare - Biotechnology - NASDAQ - US
$ 6.99
6.21 %
$ 796 M
Market Cap
-3.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COGT stock under the worst case scenario is HIDDEN Compared to the current market price of 6.99 USD, Cogent Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COGT stock under the base case scenario is HIDDEN Compared to the current market price of 6.99 USD, Cogent Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COGT stock under the best case scenario is HIDDEN Compared to the current market price of 6.99 USD, Cogent Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COGT

image
$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-276 M OPERATING INCOME
-32.58%
-256 M NET INCOME
-32.98%
-208 M OPERATING CASH FLOW
-35.26%
38.3 M INVESTING CASH FLOW
139.13%
214 M FINANCING CASH FLOW
31.13%
0 REVENUE
0.00%
-74.9 M OPERATING INCOME
-1.63%
-72 M NET INCOME
-5.98%
-66.5 M OPERATING CASH FLOW
-9.80%
69.4 M INVESTING CASH FLOW
12.50%
25 M FINANCING CASH FLOW
95938.46%
Balance Sheet Cogent Biosciences, Inc.
image
Current Assets 296 M
Cash & Short-Term Investments 287 M
Receivables 0
Other Current Assets 9.4 M
Non-Current Assets 31.4 M
Long-Term Investments 0
PP&E 26.6 M
Other Non-Current Assets 4.86 M
87.55 %2.87 %8.10 %Total Assets$327.9m
Current Liabilities 55.7 M
Accounts Payable 12 M
Short-Term Debt 1.56 M
Other Current Liabilities 42.1 M
Non-Current Liabilities 15.9 M
Long-Term Debt 15.9 M
Other Non-Current Liabilities 0
16.78 %58.83 %22.21 %Total Liabilities$71.6m
EFFICIENCY
Earnings Waterfall Cogent Biosciences, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 276 M
Operating Income -276 M
Other Expenses -20.1 M
Net Income -256 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(276m)(276m)20m(256m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-99.83% ROE
-99.83%
-78.03% ROA
-78.03%
-100.80% ROIC
-100.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cogent Biosciences, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -256 M
Depreciation & Amortization 0
Capital Expenditures -573 K
Stock-Based Compensation 39.7 M
Change in Working Capital 11.6 M
Others -202 M
Free Cash Flow -208 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cogent Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for COGT of $14.8 , with forecasts ranging from a low of $13 to a high of $17 .
COGT Lowest Price Target Wall Street Target
13 USD 85.98%
COGT Average Price Target Wall Street Target
14.8 USD 111.02%
COGT Highest Price Target Wall Street Target
17 USD 143.20%
Price
Max Price Target
Min Price Target
Average Price Target
18181616141412121010886644Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Cogent Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
332 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Cogent Biosciences Reports First Quarter 2025 Financial Results Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo. globenewswire.com - 1 month ago
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics globenewswire.com - 2 months ago
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? Cogent Biosciences (COGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. zacks.com - 3 months ago
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients 65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo. globenewswire.com - 3 months ago
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results • Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 •  APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 •  Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 •  $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo. globenewswire.com - 3 months ago
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year. zacks.com - 4 months ago
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025. globenewswire.com - 4 months ago
3 Biotech Stocks With Notable Insider Buying Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners. seekingalpha.com - 4 months ago
8. Profile Summary

Cogent Biosciences, Inc. COGT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 796 M
Dividend Yield 0.00%
Description Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Contact 200 Cambridge Park Drive, Waltham, MA, 02140 https://www.cogentbio.com
IPO Date March 29, 2018
Employees 205
Officers Mr. John L. Green C.A., CPA Chief Financial Officer & Principal Accounting Officer Dr. Jessica Sachs M.D. Chief Medical Officer Mr. Evan D. Kearns J.D. Chief Legal Officer & Corporate Secretary Mr. Dana R. Martin Pharm.D. Senior Vice President of Medical Affairs & Chief Patient Officer Ms. Erin Schellhammer Chief People Officer Mr. Andrew R. Robbins M.B.A. President, Chief Executive Officer & Director Ms. Christi Waarich Senior Director of Investor Relations Dr. John Edward Robinson Ph.D. Chief Scientific Officer Mr. Cole Pinnow Chief Commercial Officer Mr. Brad Barnett Chief Technology Officer